Sarah Bly, Director of Regulatory Science Strategy and Innovation at CRO Worldwide Clinical Trials and a member of our initiative, along with Matt Cooper, Executive Director and Therapeutic Strategy Lead in Oncology at Worldwide, discussed the EU-X-CT initiative in an interview with Clinical Trials Arena.

Although the prevalence of cross-border trials has increased due to modern technology, there is a lack of established practices for cross-border clinical trial access. They highlighted the need to establish guidance, which is the main focus of the EU-X-CT project. 

They also cautioned against setting up just one site and enrolling patients from across the continent. It&rsquos crucial to consider whether it&rsquos justifiable to ask patients to travel and how much this would affect them. It&rsquos also important to think about these factors early on and ensure that the study design fits into the patients&rsquo lives.

Read the full interview here: https://www.clinicaltrialsarena.com/interviews/euxct-projetc-clarity-europe/?cf-view